Literature DB >> 12604234

17-beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold.

William M Brown1, Louis E Metzger, Jeremy P Barlow, Lucy A Hunsaker, Lorraine M Deck, Robert E Royer, David L Vander Jagt.   

Abstract

17-beta-Hydroxysteroid dehydrogenase type 1 (17betaHSD1), also called estradiol dehydrogenase, catalyzes the NADPH-dependent reduction of the weak estrogen, estrone, into the more potent estrogen, 17-beta-estradiol. 17betaHSD1 is an attractive drug target in hormone-sensitive breast cancer. Past efforts to develop selective inhibitors of 17betaHSD1 have focused on design of substrate analogs. It is challenging to develop steroid analogs that are devoid of any undesired biological activity. 17betaHSD1 is a member of the short-chain dehydrogenase/reductase (SDR) superfamily that includes many hydroxysteroid dehydrogenases. Members of the SDR family bind NAD(P)(H) in a motif that is a modified Rossmann fold. We demonstrated previously that the Rossmann folds of classical dehydrogenases can be selectively inhibited by derivatives and analogs of the natural product gossypol. In this study, we have addressed the question whether the modified Rossmann fold in 17betaHSD1 is a target for identification of lead compounds for structure-based drug design. 17betaHSD1 was purified from human placenta. 17betaHSD1 is inhibited by derivatives of gossypol with dissociation constants as low as 2 microM. Inhibition is competitive with the binding of cofactor. Molecular modeling studies using the published coordinates of human 17betaHSD1 suggest that these inhibitors occupy the modified Rossmann fold at the nicotinamide end of the dinucleotide-binding site, extending towards the substrate site. A computational approach was used to design potential new inhibitors of 17betaHSD1. The results suggest not only that derivatives of gossypol represent attractive lead compounds for structure-based drug design but also suggest that appropriate incorporation of a substrate analog into the design of these Rossmann fold inhibitors may provide pan-active site inhibitors that span the cofactor and substrate site, potentially offering specificity and increased potency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604234     DOI: 10.1016/s0009-2797(02)00184-9

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  4 in total

Review 1.  Virtual screening applications in short-chain dehydrogenase/reductase research.

Authors:  Katharina R Beck; Teresa Kaserer; Daniela Schuster; Alex Odermatt
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-09       Impact factor: 4.292

2.  Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1.

Authors:  Gabriele Möller; Bettina Husen; Dorota Kowalik; Leena Hirvelä; Dariusz Plewczynski; Leszek Rychlewski; Josef Messinger; Hubert Thole; Jerzy Adamski
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

3.  Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) identified by virtual screening.

Authors:  Yi Wang; Tamara Noelle Hess; Victoria Jones; Joe Zhongxiang Zhou; Michael R McNeil; J Andrew McCammon
Journal:  Bioorg Med Chem Lett       Date:  2011-09-29       Impact factor: 2.823

4.  A unique co-culture model for fundamental and applied studies of human fetoplacental steroidogenesis and interference by environmental chemicals.

Authors:  Andrée-Anne Hudon Thibeault; Kathy Deroy; Cathy Vaillancourt; J Thomas Sanderson
Journal:  Environ Health Perspect       Date:  2014-01-31       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.